Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ilkova, H.
Right arrow Articles by Cerasi, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ilkova, H.
Right arrow Articles by Cerasi, E.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes Care, Vol 20, Issue 9 1353-1356, Copyright © 1997 by American Diabetes Association


ARTICLES

Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment

H Ilkova, B Glaser, A Tunckale, N Bagriacik and E Cerasi
Department of Internal Medicine, Istanbul University Cerrahpasa Medical Faculty, Turkey.

OBJECTIVE: Type 2 diabetes is a slowly progressive disease, in which the gradual deterioration of glucose tolerance is associated with the progressive decrease in beta-cell function. Hyperglycemia per se has deleterious effects on both beta-cell function and insulin action, which are partially reversible by the short-term control of blood glucose levels. We hypothesized that the induction of euglycemia, using intensive insulin therapy at the time of clinical diagnosis, could lead to a significant improvement in insulin secretion and action and thus alter the clinical course of the disease. RESEARCH DESIGN AND METHODS: Thirteen newly diagnosed diet-unresponsive type 2 diabetic patients were treated with continuous subcutaneous insulin infusion (CSII) for 2 weeks and followed longitudinally while being treated with diet alone. RESULTS: Four patients were considered therapeutic failures since CSII failed to induce euglycemia (n = 1) or glucose control deteriorated within 6 months after CSII (n = 3). The remaining nine patients were maintained on diet alone with adequate control from 9 to > 50 months (median +/- SE, 26 +/- 4.8 months). In five patients, glycemic control deteriorated after 9-36 months, but a repeat 2-week CSII treatment reestablished control in four patients. One of these patients underwent a third CSII treatment 13 months later. At the time this article was written, six patients of the initial group were still controlled without medication 16-59 months (median +/- SE, 45.5 +/- 6.6 months) after the initiation of treatment. Body weight remained unchanged in all patients. CONCLUSIONS: These findings suggest that in a significant proportion of type 2 diabetic patients who fail to respond to dietary measures, short-term intensive insulin treatment can effectively establish responsiveness, allowing long-term glycemic control without medication. Further studies are required to establish whether simpler treatment regimens could be equally effective. If the hypothesis offered here finds support, present approaches to the management of newly diagnosed type 2 diabetes may need to be revised.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Diabetes CareHome page
M. B. Davidson
No Need for the Needle (at First)
Diabetes Care, October 1, 2008; 31(10): 2070 - 2071.
[Full Text] [PDF]


Home page
The Diabetes EducatorHome page
M. E. Larkin, V. A. Capasso, C.-L. Chen, E. K. Mahoney, B. Hazard, E. Cagliero, and D. M. Nathan
Measuring Psychological Insulin Resistance: Barriers to Insulin Use
The Diabetes Educator, May 1, 2008; 34(3): 511 - 517.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
M. Massi-Benedetti and M. Orsini-Federici
Treatment of Type 2 Diabetes With Combined Therapy: What are the pros and cons?
Diabetes Care, February 1, 2008; 31(Supplement_2): S131 - S135.
[Abstract] [Full Text] [PDF]


Home page
J Clin PharmacolHome page
D. Q. Pham, H. Cohen, and V. Chu
Inhaled Human [rDNA Origin] Insulin, a Novel Formulation for Diabetes Mellitus
J. Clin. Pharmacol., July 1, 2007; 47(7): 890 - 903.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
B. L. Wajchenberg
{beta}-Cell Failure in Diabetes and Preservation by Clinical Treatment
Endocr. Rev., April 1, 2007; 28(2): 187 - 218.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
E. Ferrannini, S. Camastra, A. Gastaldelli, A. Maria Sironi, A. Natali, E. Muscelli, G. Mingrone, and A. Mari
Beta-Cell Function in Obesity: Effects of Weight Loss
Diabetes, December 1, 2004; 53(suppl_3): S26 - S33.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
Y. Li, W. Xu, Z. Liao, B. Yao, X. Chen, Z. Huang, G. Hu, and J. Weng
Induction of Long-term Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients Is Associated With Improvement of {beta}-Cell Function
Diabetes Care, November 1, 2004; 27(11): 2597 - 2602.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
E. A. Ryan, S. Imes, and C. Wallace
Short-Term Intensive Insulin Therapy in Newly Diagnosed Type 2 Diabetes
Diabetes Care, May 1, 2004; 27(5): 1028 - 1032.
[Abstract] [Full Text] [PDF]


Home page
British Journal of Diabetes & Vascular DiseaseHome page
P. Hammond
Continuous subcutaneous insulin infusion: short-term benefits apparent, long-term benefits speculative
The British Journal of Diabetes & Vascular Disease, March 1, 2004; 4(2): 104 - 108.
[Abstract] [PDF]


Home page
Diabetes CareHome page
P. Raskin, B. W. Bode, J. B. Marks, I. B. Hirsch, R. L. Weinstein, J. B. McGill, G. E. Peterson, S. R. Mudaliar, and R. R. Reinhardt
Continuous Subcutaneous Insulin Infusion and Multiple Daily Injection Therapy Are Equally Effective in Type 2 Diabetes: A randomized, parallel-group, 24-week study
Diabetes Care, September 1, 2003; 26(9): 2598 - 2603.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
S. A. Westphal and P. J. Palumbo
Insulin and Oral Hypoglycemic Agents Should Not Be Used in Combination in the Treatment of Type 2 Diabetes
Arch Intern Med, August 11, 2003; 163(15): 1783 - 1785.
[Full Text] [PDF]


Home page
NEJMHome page
D. M. Nathan
Initial Management of Glycemia in Type 2 Diabetes Mellitus
N. Engl. J. Med., October 24, 2002; 347(17): 1342 - 1349.
[Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
S. Park and S. B. Choi
Effects of {alpha}-tocopherol supplementation and continuous subcutaneous insulin infusion on oxidative stress in Korean patients with type 2 diabetes
Am. J. Clinical Nutrition, April 1, 2002; 75(4): 728 - 733.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
M. J. Lenhard and G. D. Reeves
Continuous Subcutaneous Insulin Infusion: A Comprehensive Review of Insulin Pump Therapy
Arch Intern Med, October 22, 2001; 161(19): 2293 - 2300.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
D. M. Nathan
Inhaled Insulin for Type 2 Diabetes: Solution or Distraction?
Ann Intern Med, February 6, 2001; 134(3): 242 - 244.
[Full Text] [PDF]


Home page
ANN INTERN MEDHome page
R. A. DeFronzo
Pharmacologic Therapy for Type 2 Diabetes Mellitus
Ann Intern Med, August 17, 1999; 131(4): 281 - 303.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1997 by the American Diabetes Association.